Barclays PLC Purchases 39,542 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

Barclays PLC increased its holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 291.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 53,089 shares of the company’s stock after purchasing an additional 39,542 shares during the period. Barclays PLC owned approximately 0.10% of Cardiff Oncology worth $141,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. State Street Corp increased its holdings in shares of Cardiff Oncology by 3.4% in the 3rd quarter. State Street Corp now owns 832,652 shares of the company’s stock worth $2,223,000 after buying an additional 27,628 shares during the last quarter. MAI Capital Management grew its position in Cardiff Oncology by 0.7% in the third quarter. MAI Capital Management now owns 663,363 shares of the company’s stock worth $1,771,000 after acquiring an additional 4,569 shares in the last quarter. Blair William & Co. IL increased its stake in Cardiff Oncology by 32.2% during the second quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock worth $505,000 after acquiring an additional 55,450 shares during the last quarter. GSA Capital Partners LLP raised its position in Cardiff Oncology by 432.7% during the third quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after purchasing an additional 151,613 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Cardiff Oncology by 82.9% in the 2nd quarter. Renaissance Technologies LLC now owns 157,490 shares of the company’s stock valued at $350,000 after purchasing an additional 71,390 shares during the last quarter. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Insider Activity at Cardiff Oncology

In other news, Director Gary W. Pace purchased 350,115 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were purchased at an average price of $2.60 per share, for a total transaction of $910,299.00. Following the completion of the purchase, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This represents a 50.18 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 7.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CRDF shares. Piper Sandler boosted their target price on Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. HC Wainwright dropped their target price on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, November 8th.

Cardiff Oncology Trading Down 9.5 %

Shares of CRDF opened at $4.11 on Wednesday. The firm has a fifty day moving average price of $3.43 and a 200-day moving average price of $2.79. The firm has a market capitalization of $210.16 million, a P/E ratio of -4.37 and a beta of 1.76. Cardiff Oncology, Inc. has a 12-month low of $1.44 and a 12-month high of $6.42.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.